Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Halaven | Eribulin Mesylate | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Aimovig | erenumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Balversa | erdafitinib | locally advanced unresectable or metastatic urothelial carcinoma (UC) | Pending | |||
| Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Teveten Plus | Eprosartan mesylate/ hydrochlorothiazide | Hypertension, Essential | List in a similar manner to other drugs in class | Complete | ||
| TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
| Inspra | Eplerenone | Heart failure, NYHA class II | Do not list at the submitted price | Complete | ||
| Inspra | Eplerenone | Post myocardial infarction | Do not list | Complete | ||
| Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
| Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 16, 2024